The objective of this study was to evaluate the budget impact of a new prostate cancer risk index for detecting prostate cancer. The index is calculated as the combination of serum prostate-specific antigen (PSA), free PSA and a precursor form p2PSA. We constructed two budget impact models using PSA cutoff values of X2 ng ml À1 (model #1) and X4 ng ml À1 (model #2) for recommending a prostate biopsy in a hypothetical health plan with 100 000 male members aged 50-75 years old. The budgetary impact on the 1-year expected total costs for prostate cancer detection was calculated. Adding the index to the current PSA prostate cancer testing strategies including the total PSA and percent free PSA, the number of detected cancer cases decreased by 20 and 5, in models #1 and #2, respectively. The savings on expected 1-year cost for prostate cancer detection were $356 647 (or $0.30 per-member-per-month (PMPM)) in model #1 and $94 219 ($0.08 PMPM) in model #2. The index produced higher cost savings in the model #1 with PSA cutoff X2 ng ml À1 than the model #2 with cutoff X4 ng ml À1 with a small short-term reduction in the number of positive tests.
Introduction
Prostate cancer is the most prevalent malignancy and the second leading cause of death among men in the United States. 1 Although routine prostate cancer screening is controversial, 2 the guidelines from the American Urological Association (AUA) 3 and the American Cancer Society 4 recommend serum prostate-specific antigen (PSA) testing for men with counseling regarding risks and benefits of prostate cancer screening. PSA level measurement and digital rectal examination remains the preferred approach for early prostate cancer detection. [5] [6] [7] A PSA cutoff level X4 ng ml À1 is widely recommended for prostate biopsy although this value has B20% sensitivity and 60% specificity for prostate cancer. 8, 9 As lowering the threshold value may improve sensitivity, [10] [11] [12] many clinicians now recommend a prostate biopsy at lower PSA values. Although this may improve the likelihood of detecting cancers, lowering the threshold value increases the identification of clinically insignificant tumors. 13 To improve PSA specificity, several PSA derivatives or biomarkers, and test methods have been suggested, including age-specific reference ranges for serum PSA, the ratio of free to total PSA (percent free PSA (%fPSA)), complexed PSA, PSA velocity and PSA density. [14] [15] [16] [17] In addition, some precursor forms of PSA (p2PSA, for example) have recently demonstrated their potential usefulness in the early detection of prostate cancer. 15, [18] [19] [20] All strategies may significantly reduce false positive results among men with total PSA 2.5-4.0 ng ml À1 (ref. 18) . Furthermore, previous studies have demonstrated that combinations of PSA, fPSA, and p2PSA in a multivariate model may achieve 41-44% clinical specificity at 90% sensitivity, as compared with individual markers (23% specificity for PSA and 18-33% specificity for %fPSA). 19, 20 Access Hybritech p2PSA has being investigated for use with Access Hybritech PSA and fPSA to calculate a multivariate index developed by Beckman Coulter (Brea, CA, USA) to determine the individuals' relative risk of prostate cancer. [21] [22] [23] Currently, a multicenter clinical study in the United States sponsored by Beckman Coulter suggests that, at 95% sensitivity, this prostate cancer risk index doubled the specificity of prostate cancer detection relative to %fPSA for individuals with PSA 2-10 ng ml À1 (ref. 21) . Although the index is not currently available for commercial distribution in the United States, an economic evaluation of the index may inform how multiple measures might affect prostate cancer management costs. The present study evaluates the 1-year budget impact to a health plan of adding the index to conventional PSA and fPSA blood tests.
Materials and methods

Population estimates
The model used a hypothetical health plan with 100 000 men aged 50-75 years old. The number of males undergoing PSA tests for prostate cancer detection was estimated based on the 2009 U.S. Census data for the population age distribution and published annual prevalence data. 24, 25 
Model description
The budget impact model used the most recent AUA recommendation for prostate cancer screening. 3 Three PSA testing strategies were compared: (1) PSA, (2) %fPSA, and (3) the index. Strategies (1) and (2) Probability of PSA 2-10 ng ml À1 ¼ (probability of PSAX2 ng ml À1 )À(probability of PSA410 ng ml À1 ); (probability of PSA 4-10 ng ml À1 ) ¼ (probability of PSAX4 ng ml À1 )À(probability of PSA410 ng ml À1 ) b Data were obtained from a simulation study by Beckman Coulter, which is currently under FDA review. c Probability of prostate cancer in PSA 2-10 ng ml À1 ¼ ((Probability of PSAX2 ng ml
À1
) * (probability of prostate cancer of PSAX2 ng ml
)À(Probability of PSA410 ng ml À1 ) * (probability of prostate cancer of PSA 410 ng ml À1 ))/(probability of PSA 2-10 ng ml
). a value of o25% for %fPSA or a score higher than 25 for the index corresponds to B30% of weighted average relative risk of prostate cancer. 21 These values represent a positive test used for an urologist visit referral and biopsy. Conversely, a %fPSA value of 25% or higher or an index score of 25 or less is considered negative, with no biopsy.
Data sources and input data
Probabilities of positive PSA test results and cancer detection were derived from the published literature. Where data were unavailable, probabilities were derived, as follows.
Probability of PSA test results. Age-specific prevalence for each PSA range was determined according to population-based United States data (Table 1) . 26 Ninety-five percent confidence intervals were used for the sensitivity analyses. Other published studies with similar data 27, 33, 34 were not applied in the model, because they did not provide age-specific prevalence. As the probability of PSA values in the equivocal ranges 2 or 4 ng ml À1 to 10 ng ml À1 was not available from the literature, it was calculated as the difference between the probability of PSA4cutoff value and the probability of PSA 410 ng ml
À1
. The positive test probabilities for %fPSA and the index were obtained from the Beckman Coulter simulation study. 21 Probability of prostate cancer detection. Among individuals who had a positive PSA test result, the prostate cancer detection rate upon biopsy was determined from published studies (Table 1) .
Costs. Base case costs were obtained from the 2009
Medicare national fee schedule. The sensitivity analysis was performed on the base case costs ±25%. Direct health care costs for relevant physician visits, diagnostic tests and procedures were included. (Table 2) .
Office visit costs included one primary care visit for the individuals with a negative PSA test, or one primary care visit and two urologist visits for those with a positive test for PSA, or %fPSA, or the index (one visit for biopsy and one for follow-up consultation). We assumed all screened men had a negative digital rectal examination in the model.
The cost of PSA blood tests depended on the PSA test result. If PSA was less than the cutoff value or 410 ng ml
À1
, one PSA test was included. If the PSA test result is borderline, the follow-up testing strategy included the following: (1) two PSA test costs (one at the primary care visit and the other at the urologist visit) for the PSA strategy; (2) one PSA and one fPSA for the %fPSA testing strategy; (3) one PSA, one fPSA and one p2PSA for the index testing strategy.
We assumed that routine urinalysis was performed for positive PSA blood tests. As prostate biopsies involve multiple procedures, costs included 12-core prostate biopsy, echography-guided biopsy, transrectal ultrasound, tissue examination by a pathologist and three immunohistochemistry stains.
Market share. Base case market share for the PSA strategy was estimated as 90, and 10% for the %fPSA strategy. In the new scenario, we assumed a 10% market share for the index strategy and maintenance of 10% for the %fPSA strategy, and 80% for the PSA strategy.
Analysis
We compared the expected 1-year total costs for prostate cancer detection between the reference and new scenarios.
First, the PSA test results were assessed. The total number of positive PSA tests was calculated as the number of men receiving a PSA test multiplied by the probability of a positive PSA test. The number of detected prostate cancers (true positive PSA test) was calculated as the number of positive PSA tests multiplied by the probability of prostate cancer, in which prostate cancer was confirmed via biopsy for the individuals with a positive PSA test. The number of unnecessary biopsies (false positive PSA test) was defined as the individuals who have a positive PSA test, with a subsequent nonconfirmatory biopsy.
Second, we calculated the total costs for all strategies, which included costs for office visits, digital rectal examination procedures, PSA blood tests, other laboratory tests and Budget impact of a prostate cancer risk index MB Nichol et al
Table 3a
Base case budget impact analysis results for PSA biopsy threshold of 2 ng ml 
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Table 3b
Base case budget impact analysis results for PSA biopsy threshold of 4 ng ml Finally, sensitivity analyses were performed to determine the influence of varied inputs on the total costs. We assumed the health plan perspective for a 1-year horizon. Costs were not discounted due to the short length of the analysis. 35 Analyses were repeated for two models of PSA cutoffs (2 and 4 ng ml À1 ) using Microsoft Office Excel 2003, and followed the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) principles of good practice for budget impact analysis. 35 The study was approved by the Institutional Review Board of the principal investigator's institution. Two coauthors from Beckman Coulter participated in study design and manuscript development. Final approval of the manuscript was the responsibility of the corresponding author.
Results
Budget impact analysis
The model evaluated the diagnostic pathway for 33 236 members receiving at least one PSA blood test for detecting prostate cancer.
The new scenario resulted in a decrease of 20 and 5 detected prostate cancers, as well as 158 and 42 cases of unnecessary biopsies, which corresponded to the decrease in the expected total number of false positive tests by 3.0, and 2.8%, in models of PSA cutoff 2 and 4 ng ml
À1
, respectively (Tables 3a and b) . When the budget component was presented by PSA test results, the savings on the total costs for the individuals with a positive PSA test were $385 559 and $101 857 at the two thresholds, respectively. The total budget impact on total costs for individuals with a negative test ranged from $28 912 to $7638 (Figure 1) . The incremental costs for PSA blood test ranged from $51 524 to $13 611; whereas cost savings were seen for office visits ($32 795 to $8664), laboratory tests ($1954 to $516), necessary biopsies ($41 582 to $10 985) and unnecessary biopsies ($331 840 to $87 665), depending on threshold.
Ninety-three percent of the overall savings came from avoiding unnecessary biopsies. The savings on expected total 1-year costs for prostate cancer detection for each model were $356 647 (0.30 PMPM) and $94 219 (0.08 PMPM). The savings on total costs per prostate cancer case detected were $84 and $58 at the respective thresholds.
Sensitivity analysis
Changing the index cutoff score from 25 to 55 for the models of PSA cutoff 2 and 4 ng ml À1 increased the savings to $1 027 009 and $271 314, respectively. The probability of having a positive PSA test, biopsy rate and biopsy costs were major factors that affected the cost differences significantly (Figure 2 ). Cost savings decreased when the screening age threshold was reduced to 40 years, the biopsy compliance rate decreased or when p2PSA cost increased. The incremental cost of generating the index could increase to $500 from the base case assumption of $72, yet there would still be cost savings at a PSA threshold of 4 ng ml
À1
. Increasing the market share of the index strategy from 10 to 90% would increase total cost savings from $94 219 (0.08 PMPM) to $847 967 (0.71 PMPM), although this would also require a significant organizational investment for testing. When the index strategy in the new scenario has an equivalent market share of fPSA in the reference scenario, the savings of total cost would be $22 540 (0.02 PMPM) to $45 079 (0.04 PMPM) in PSA cutoff 2 ng ml À1 for 10-20% market share, respectively.
Discussion
Adding the index to the current PSA testing strategies for prostate cancer detection could produce total cost savings at both thresholds of PSA cutoff 2 ng ml À1 (0. 30 PMPM) and 4 ng ml À1 (0.08 PMPM). The index reduced the total number of both true and false positive tests in the tested population, which may decrease the number of office visits, laboratory tests and prostate . PSA, prostate specific antigen.
Budget impact of a prostate cancer risk index MB Nichol et al biopsies. Where p2PSA is commercially available, the unit cost is B2-3 times higher than either PSA or fPSA, so the use of the index for prostate cancer detection increased the total blood test costs by $51 524 and $13 611 for the models with PSA cutoff of 2 and 4 ng ml À1 , respectively. However, these additional blood test costs were offset by the savings on the costs of office visits (À$32 795 to À$8664), laboratory tests (À$1954 to À$516) and biopsies (À$373 422 to À$98 650), depending on the thresholds.
Comparing the models between PSA cutoff 2 and 4 ng ml
À1
, the savings in the model of 2 ng ml À1 were B2.6 times of those in the model of 4 ng ml
. Lowering the PSA cutoff increased test sensitivity, therefore increasing the total number of positive tests overall. However, compared with the reference scenario, the introduction of the index reduced more cases of positive tests in the 2 ng ml À1 model than in the 4 ng ml À1 model (that is, a difference of 178 and 47 cases between scenarios, respectively). This may have led to the higher savings in the threshold 2 ng ml À1 analysis. Most of the savings (92%) were realized by reducing unnecessary biopsies through increased index specificity. The overall reduction in biopsies resulting from a decrease in the number of positive PSA tests yielded a modest 2% decline for both screening thresholds. There were few missed cases, but these produced 12% of the overall savings. These missed cases came from two sources. First, the models were constructed using threshold values to determine a positive test. Other modeling methods, such as using a continuous cancer risk score to determine relative cancer risk in the model could limit missed cases. Second, false negative tests produced missed cases, which could be minimized by increasing specificity. Cases missed at initial screening generate relatively few poor outcomes, as the false negative cases are likely to be found in subsequent screenings. 28 There is some evidence that missed prostate cancers have relatively low Gleason scores (average 6 (3 þ 3) ). 36 Moreover, some studies indicate that most cancers detected at 2 to 4 years after an initial screen (first round) will be curable. [37] [38] [39] [40] [41] [42] A study of an individualized screening algorithm showed that very few important prostate cancers, for which diagnosis at a subsequent screening visit might be too late for treatment with curative intent, would be missed.
When reducing the screening age threshold to 40 years, consistent with the proposed guidelines from AUA, the total screening costs and the savings from adding the index were smaller than those for the screening population with age 50-75 years. Younger men of age 40-49 years old were less likely to have a PSA test and to have a positive test result than older men. The number of tested men and required biopsies were . fPSA, free PSA; PSA, prostate specific antigen; tPSA, total PSA.
Budget impact of a prostate cancer risk index MB Nichol et al smaller in the screening population with lower age threshold, which produced less total screening costs and savings.
This analysis has several limitations. First, we have not counted the potential clinical and economic impact from missed diagnoses due to PSA false negative test results, as we assumed that all negative PSA tests were correct. However, the missed cases are usually detected in subsequent screenings. 28, 36 Second, we modeled prostate cancer detection using biopsy threshold values instead of the probability of prostate cancer risk. Research suggests that the higher levels of PSA are associated with increased risk of cancer. 32, 43 Although these values are used to determine the need for biopsies, studies have demonstrated that the use of a 4 ng ml À1 cutoff was unable to detect all prostate cancers. 13, 43 Moreover, some cancers detected at very low PSA levels have proven incurable. 12 Although there is some evidence that the field is now using a 2 ng ml À1 cutoff, lowering the biopsy threshold may increase detection of 'indolent' lesions. 13, 29, 30, [43] [44] [45] Therefore, the 2009 AUA PSA Best Practice Policy 3 emphasizes that the prostate biopsy decision should consider PSA and digital rectal examination results, as well as multiple factors. Two recent studies 22, 23 reported that a mathematical formula combining total PSA, fPSA and p2PSA to calculate the index shows improved specificity for detecting prostate cancer. Jansen et al. 22 reported a specificity of 31% for the index at 90% sensitivity, compared with total PSA (10%) and %fPSA (12%). Comprehensive prostate cancer risk calculators have been developed to assess individual risk 32, 46 of cancer or need for biopsy and follow-up. Although applying a risk score within the budget impact model may have provided a more precise economic evaluation, the lack of available data restricted such an application.
In summary, the index shows considerable promise as a complementary approach to current prostate cancer screening strategies as one method for cost reduction. The 1-year budget impact model showed that the increased laboratory costs required for this application resulted in health care cost savings from reductions in physician office visits, and the avoidance of unnecessary biopsy procedures. Future studies should address the impact of the new screening strategy on identifying prostate cancers over multiple years, and the consequent treatment costs and mortality.
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